133 results
425
LJPC
La Jolla Pharmaceutical Co.
7 Dec 09
Business combination disclosure
12:00am
not to exceed 3,286,132 shares.
On December 4, 2009, the Compa ny entered into a Retention and Separation Agreement and General Release of All Claims … with Deirdre Y. Gillespie, M.D., the Company’s President and Chief Executive Officer (the "Gillespie Retention Agreement").
The Gillespie Retention
8-K
EX-10.1
DMKPQ
DMK Pharmaceuticals Corp
16 Nov 07
Entry into a Material Definitive Agreement
12:00am
November 14, 2007
Mr. Robert J. Caso
c/o Cellegy Pharmaceuticals, Inc. 2085 Quaker Pointe Drive
Quakertown, PA 18951
Re: Retention Agreement … Pharmaceuticals, Inc. (the "Company" or“Cellegy”).
1. Retention Payment. As an incentive for you (sometimes referred to as “Employee”) to remain employed
8-K
DMKPQ
DMK Pharmaceuticals Corp
16 Nov 07
Entry into a Material Definitive Agreement
12:00am
into a retention agreement. The description below is qualified in its entirety by the full text of the retention agreement, which is filed herewith … of (i) June 30, 2008 and (ii) the closing of a change in control transaction (as defined in the agreement) (the “Retention Period”), then the Company
425
EX-10.1
LJPC
La Jolla Pharmaceutical Co.
7 Dec 09
Business combination disclosure
12:00am
RETENTION AND SEPARATION AGREEMENT
AND GENERAL RELEASE OF ALL CLAIMS
This Retention and Separation Agreement and General Release of All Claims … .Retention Bonus. LJPC agrees to pay Gillespie a retention bonus of $202,800.00, less all legally required payroll deductions and withholdings (“Retention
425
EX-10.2
fyr9s08vg12 v8
7 Dec 09
Business combination disclosure
12:00am
8-K
EX-10.1
2rf3ppbi
18 May 22
Adamis Pharmaceuticals Announces Leadership Transition to Support New Phase of Innovation and Growth
7:53pm
8-K
4i12esxj2nl9sybp
31 May 05
Entry into a Material Definitive Agreement
12:00am
8-K
7blzo1wh90s8 r99
13 Sep 06
Termination of a Material Definitive Agreement
12:00am